DDInter379 DDInter899
Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Cilostazol {u} (Compound) binds {v} (Gene) PDE3A
Cilostazol {u} (Compound) upregulates {v} (Gene) RRP8
Cilostazol {u} (Compound) palliates {v} (Disease) systemic scleroderma
Cilostazol {u} (Compound) downregulates {v} (Gene) PPP2R5E
Cilostazol {u} (Compound) causes {v} (Side Effect) Arthritis
Cilostazol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Brivaracetam
Cilostazol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Cilostazol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Adenosine
Cilostazol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etravirine
Cilostazol {u} may lead to a major life threatening interaction when taken with {v} Fondaparinux
Cilostazol (Compound) binds PDE3A (Gene)
Cilostazol (Compound) upregulates RRP8 (Gene)
Cilostazol (Compound) palliates systemic scleroderma (Disease)
Cilostazol (Compound) downregulates PPP2R5E (Gene)
Cilostazol (Compound) causes Arthritis (Side Effect)
Cilostazol may cause a minor interaction that can limit clinical effects when taken with Brivaracetam
Cilostazol may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Adenosine
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Cilostazol may lead to a major life threatening interaction when taken with Fondaparinux